Search for: "Lisa Nicholson "
Results 41 - 60
of 83
Sorted by Relevance
|
Sort by Date
27 May 2020, 12:00 pm
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
3 May 2021, 8:36 am
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceWe have written before about the challenges of making decisions under scientific uncertainty and the simultaneous importance and difficulty of developing high-quality clinical evidence under pandemic circumstances. [read post]
30 Nov 2020, 7:24 am
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceWhen President-elect Joe Biden is inaugurated in January, his administration will face the ongoing public health and economic challenges created by COVID-19. [read post]
6 Dec 2021, 6:24 am
By Nicholson Price, Rachel Sachs, Jacob S. [read post]
3 Mar 2022, 6:43 am
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsSince the pandemic began, numerous recovered COVID-19 patients have reported having “long COVID”: COVID-19 symptoms persisting well beyond the underlying viral infection period. [read post]
30 Oct 2020, 12:50 pm
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
27 Aug 2021, 12:18 pm
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceIn previous blog posts in this series, we have explored the roles different federal agencies, including the NIH, FDA, and CMS, play in the development and distribution of new healthcare technologies in the fight against COVID-19. [read post]
9 Apr 2021, 8:03 am
By Nicholson Price, Rachel Sachs, Jacob S. [read post]
9 Feb 2017, 10:51 am
And Defense One tells us that General John Nicholson testified to Congress that Afghanistan needs “thousands” more troops if it is to turn the tide of the “stalemate” that currently exists in the country. [read post]
2 Oct 2020, 7:10 am
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceIn recent weeks, a number of articles have reported great concern around the politicization of the approval process for future COVID-19 vaccines. [read post]
2 Jun 2020, 10:31 pm
By Nicholson Price, Rachel Sachs, Jacob S. [read post]
5 Aug 2020, 11:43 am
By Nicholson Price, Rachel Sachs, Jacob S. [read post]
4 Mar 2021, 10:50 am
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsAre patents the cause of—or solution to—COVID-19 vaccine innovation problems? [read post]
30 Mar 2020, 8:40 am
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowOne of the dizzying stream of innovation and health law stories to emerge last week is Oracle’s partnership with the White House to study unproven pharmaceuticals for treating COVID-19. [read post]
30 Jul 2021, 5:03 am
By Nicholson Price, Rachel Sachs, Jacob S. [read post]
18 Jun 2020, 1:23 pm
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsIn the United States, one of the most important factors in receiving COVID-19 testing or treatment is access to insurance. [read post]
13 Aug 2020, 8:09 am
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceIn this blog post series, we have written about the importance of ensuring an adequate supply of diagnostic testing for COVID-19, and about the challenges the United States has faced so far on this front. [read post]
12 Jan 2021, 9:04 am
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Why is HHS blocking FDA from regulating some diagnostics, and how will this affect COVID-19 testing?
25 Aug 2020, 4:50 pm
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
19 May 2020, 3:30 pm
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsLast week, we focused on incentives for developing clinical evidence supporting the use of remdesivir for COVID-19 and analyzed the FDA’s grant of an emergency use authorization (EUA) for the drug. [read post]
